Prescription medicines with potential for foetal harm: dispensing before and during pregnancy in New Zealand, 2005–2015
- 4 April 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Clinical Pharmacology
- Vol. 76 (6), 887-896
- https://doi.org/10.1007/s00228-020-02868-2
Abstract
This study describes dispensing of potentially teratogenic prescription medicines before and during pregnancy in New Zealand over the period 2005–2015.Keywords
Funding Information
- Health Research Council of New Zealand (16/072)
This publication has 23 references indexed in Scilit:
- Use of real‐world evidence from healthcare utilization data to evaluate drug safety during pregnancyPharmacoepidemiology and Drug Safety, 2019
- Generation of a pregnancy cohort for medicine utilisation and medicine safety studies in New ZealandPharmacoepidemiology and Drug Safety, 2018
- Classifying drugs in pregnancyAustralian Prescriber, 2014
- Evolving knowledge of the teratogenicity of medications in human pregnancySeminars in Medical Genetics, Part C of the American Journal of Medical Genetics, 2011
- Patterns of pregnancy exposure to prescription FDA C, D and X drugs in a Canadian populationJournal of Perinatology, 2008
- An Introduction to Categorical Data AnalysisWiley Series in Probability and Statistics, 2006
- Use of prescription medications with a potential for fetal harm among pregnant womenPharmacoepidemiology and Drug Safety, 2006
- Teratogenicity of recently introduced medications in human pregnancyObstetrics & Gynecology, 2002
- Review of pregnancy labeling of prescription drugs: Is the current system adequate to inform of risks?American Journal of Obstetrics and Gynecology, 2002
- FDA classification of drugs for teratogenic risk: Teratology society public affairs committeeTeratology, 1994